CL2013001602A1 - Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. - Google Patents
Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.Info
- Publication number
- CL2013001602A1 CL2013001602A1 CL2013001602A CL2013001602A CL2013001602A1 CL 2013001602 A1 CL2013001602 A1 CL 2013001602A1 CL 2013001602 A CL2013001602 A CL 2013001602A CL 2013001602 A CL2013001602 A CL 2013001602A CL 2013001602 A1 CL2013001602 A1 CL 2013001602A1
- Authority
- CL
- Chile
- Prior art keywords
- neuroprotection
- fatigue
- level
- reduce
- multiple sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42074210P | 2010-12-07 | 2010-12-07 | |
US201161542996P | 2011-10-04 | 2011-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013001602A1 true CL2013001602A1 (es) | 2013-10-25 |
Family
ID=46162796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013001602A CL2013001602A1 (es) | 2010-12-07 | 2013-06-05 | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20120142730A1 (es) |
EP (1) | EP2648732A4 (es) |
JP (2) | JP2013544887A (es) |
KR (1) | KR20130124518A (es) |
CN (1) | CN103260624B (es) |
AU (2) | AU2011338647A1 (es) |
BR (1) | BR112013014061A2 (es) |
CA (1) | CA2820586A1 (es) |
CL (1) | CL2013001602A1 (es) |
EA (1) | EA201390827A1 (es) |
IL (1) | IL250726A0 (es) |
MX (1) | MX2013006464A (es) |
NZ (1) | NZ611628A (es) |
PE (1) | PE20140872A1 (es) |
SG (2) | SG10201509831XA (es) |
UA (1) | UA111959C2 (es) |
WO (1) | WO2012078591A1 (es) |
ZA (1) | ZA201304237B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1937642B1 (en) * | 2005-10-19 | 2014-09-10 | Teva Pharmaceutical Industries Ltd | Crystals of laquinimod sodium, and process for the manufacture thereof |
ES2600920T3 (es) | 2007-12-20 | 2017-02-13 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
MX2012001333A (es) * | 2009-07-30 | 2012-06-01 | Teva Pharma | Tratamiento de la enfermedad de crohn con la laquinimod. |
AU2010282948C1 (en) | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
US8501766B2 (en) * | 2010-03-03 | 2013-08-06 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
CN102791130B (zh) * | 2010-03-03 | 2015-02-25 | 泰华制药工业有限公司 | 使用拉喹莫德治疗狼疮肾炎 |
EP2597954A4 (en) | 2010-07-09 | 2014-01-01 | Teva Pharma | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF |
EA201490748A1 (ru) | 2011-10-12 | 2014-12-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза комбинацией лахинимода и финголимода |
KR20140138694A (ko) | 2012-02-03 | 2014-12-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도 |
AR090073A1 (es) | 2012-02-16 | 2014-10-15 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
WO2014052933A1 (en) * | 2012-09-27 | 2014-04-03 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
US20140107154A1 (en) * | 2012-10-12 | 2014-04-17 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
CA2890194A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
AU2014216199A1 (en) * | 2013-02-15 | 2015-09-03 | Teva Pharmaceutical Industries Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
BR112015021602A2 (pt) | 2013-03-14 | 2017-07-18 | Teva Pharma | cristais de laquinimod de sódio e processo melhorado para a fabricação dos mesmos |
WO2014152009A1 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
TW201609098A (zh) * | 2013-12-20 | 2016-03-16 | 泰瓦藥品工業有限公司 | 拉喹莫德(laquinimod)於延緩亨丁頓舞蹈症進展的用途 |
US20160331742A1 (en) * | 2014-01-17 | 2016-11-17 | Teva Pharmaceutical Industries, Ltd. | Treatment of crohn's disease using low doses of laquinimod |
EP3137092A4 (en) | 2014-04-29 | 2017-10-11 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
AU2015332037A1 (en) * | 2014-10-16 | 2017-04-27 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
CN112770748A (zh) * | 2018-10-09 | 2021-05-07 | 美迪诺亚公司 | 异丁司特和干扰素-β的组合及其使用方法 |
TW202116308A (zh) * | 2019-07-22 | 2021-05-01 | 瑞士商艾克泰聯製藥有限公司 | 治療多發性硬化症之方法 |
CN110688373A (zh) * | 2019-09-17 | 2020-01-14 | 杭州绿度信息技术有限公司 | 一种基于逻辑回归的offset方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE028833T2 (en) * | 2004-09-09 | 2017-01-30 | Yeda Res & Dev | Polypeptide mixtures, compositions containing them, process for their preparation, and applications |
US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
DK2035001T3 (da) * | 2006-06-12 | 2012-02-27 | Teva Pharma | Stabile laquinimod-tilberedninger |
EP4137819A1 (en) * | 2007-02-08 | 2023-02-22 | Biogen MA Inc. | Compositions and uses for treating multiple sclerosis |
MX2011013902A (es) * | 2009-06-19 | 2012-02-23 | Teva Pharma | Tratamiento de esclerosis multiple con laquinimod. |
-
2011
- 2011-12-06 AU AU2011338647A patent/AU2011338647A1/en not_active Abandoned
- 2011-12-06 BR BR112013014061A patent/BR112013014061A2/pt not_active Application Discontinuation
- 2011-12-06 UA UAA201308448A patent/UA111959C2/uk unknown
- 2011-12-06 PE PE2013001357A patent/PE20140872A1/es not_active Application Discontinuation
- 2011-12-06 CN CN201180060414.8A patent/CN103260624B/zh not_active Expired - Fee Related
- 2011-12-06 CA CA2820586A patent/CA2820586A1/en not_active Abandoned
- 2011-12-06 WO PCT/US2011/063460 patent/WO2012078591A1/en active Application Filing
- 2011-12-06 KR KR1020137017362A patent/KR20130124518A/ko not_active Application Discontinuation
- 2011-12-06 SG SG10201509831XA patent/SG10201509831XA/en unknown
- 2011-12-06 JP JP2013543255A patent/JP2013544887A/ja active Pending
- 2011-12-06 US US13/312,284 patent/US20120142730A1/en not_active Abandoned
- 2011-12-06 EP EP11846599.6A patent/EP2648732A4/en not_active Withdrawn
- 2011-12-06 SG SG2013042403A patent/SG190449A1/en unknown
- 2011-12-06 MX MX2013006464A patent/MX2013006464A/es unknown
- 2011-12-06 EA EA201390827A patent/EA201390827A1/ru unknown
- 2011-12-06 NZ NZ611628A patent/NZ611628A/en not_active IP Right Cessation
-
2013
- 2013-06-05 CL CL2013001602A patent/CL2013001602A1/es unknown
- 2013-06-10 ZA ZA2013/04237A patent/ZA201304237B/en unknown
-
2016
- 2016-12-26 JP JP2016251360A patent/JP2017095476A/ja active Pending
-
2017
- 2017-02-22 IL IL250726A patent/IL250726A0/en unknown
- 2017-03-28 AU AU2017202055A patent/AU2017202055A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
UA111959C2 (uk) | 2016-07-11 |
EP2648732A4 (en) | 2014-04-30 |
WO2012078591A1 (en) | 2012-06-14 |
BR112013014061A2 (pt) | 2016-09-13 |
CN103260624B (zh) | 2015-06-03 |
SG10201509831XA (en) | 2015-12-30 |
PE20140872A1 (es) | 2014-08-09 |
CN103260624A (zh) | 2013-08-21 |
NZ611628A (en) | 2015-06-26 |
AU2011338647A1 (en) | 2013-07-04 |
JP2013544887A (ja) | 2013-12-19 |
US20120142730A1 (en) | 2012-06-07 |
JP2017095476A (ja) | 2017-06-01 |
EP2648732A1 (en) | 2013-10-16 |
MX2013006464A (es) | 2013-07-29 |
AU2017202055A1 (en) | 2017-04-20 |
IL250726A0 (en) | 2017-04-30 |
EA201390827A1 (ru) | 2013-12-30 |
WO2012078591A8 (en) | 2012-08-02 |
AU2011338647A8 (en) | 2013-09-05 |
SG190449A1 (en) | 2013-07-31 |
ZA201304237B (en) | 2014-08-27 |
KR20130124518A (ko) | 2013-11-14 |
CA2820586A1 (en) | 2012-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
CL2015003690A1 (es) | Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. | |
CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
EA201500934A1 (ru) | Кардио- и нефропротективная противодиабетическая терапия | |
CL2013003679A1 (es) | Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas. | |
CL2013003639A1 (es) | Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas. | |
IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
IT1400982B1 (it) | Collirio osmotico trans-epiteliale per la cura del cheratocono. | |
CU20120161A7 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas | |
SI2739615T1 (sl) | Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo | |
WO2013003669A3 (en) | Compositions, methods of use, and methods of treatment | |
MX366090B (es) | Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2. | |
PE20151435A1 (es) | Laquinimod para reducir el dano talamico en la esclerosis multiple | |
EP2582682A4 (en) | METHOD FOR THE TREATMENT OF LUNG DISEASES | |
CL2013003143A1 (es) | Uso de compuestos derivados de fenilaminopirimidinilo, un enantiomero o una sal farmaceuticamente aceptable del mismo para reducir la viabilidad de celulas de mieloma multiple en un estado de celulas no erspondedoras a il-6 y/o que tienen un fenotipo cd45-. | |
CL2013002905A1 (es) | Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares. | |
CL2013003198A1 (es) | Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas. | |
BR112014009789A2 (pt) | cisteamina no tratamento da doença fibrótica | |
CL2013003230A1 (es) | Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de tumores sólidos avanzados y/o metastásicos. | |
CL2013002193A1 (es) | Uso de un producto que comprende macitentano o una sal del mismo en combinacion con un agente alquilante o un inhibidor mitotico para preparar un medicamento util en el tratamiento de glioma maligno. | |
AR080933A1 (es) | Tratamiento de esclerosis multiple con masitinib | |
CL2014000992A1 (es) | Preparacion de liberacion sostenida que comprende pioglitazona o una sal de esta; metodo de preparacion; uso para prevenir y/o retardar el inicio o suprimir la progresion de la enfermedad de alzheimer. | |
ES2545508T3 (es) | Uso de ácido benzoico o una sal del mismo para reducir trastornos del tracto urinario en rumiantes | |
UY33789A (es) | Combinación que comprende un derivado de la familia de las combretastatinas y cetuximab |